STUDY PLEA: Biopharmaceutical group KS Biomedix is seeking approval to move its anti-inflammatory drug KSB301 into the next phase of clinical development.
TAKING OVER: Entertainment and events services group Wembley, based in Wembley, London, said chief executive Nigel Potter had been forced to take a temporary leave of absence to undergo surgery. Claes Hultman, chairman, will take over his executive responsibilities.
ON TOP: Hat Pin, which provides recruitment services to the broadcast industry, said full year results would be "materially higher than current market expectations".
BRIAN'S BID: Brian Leckie, chief executive of wallcoverings-to-umbrella frames maker Chapelthorpe, has made an "indicative approach" to buy the group.
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules hereComments are closed on this article